Navigation Links
GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
Date:10/6/2010

GAITHERSBURG, Md., Oct. 6 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has executed its first option period (year two) under a previously announced four year-contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).  GenVec will receive up to approximately $3.5 million for the second year of activities under the SAIC contract. This funding increases the total value of the contract, originally valued at $22 million, to up to approximately $24 million. These funds will continue to support the development of new HIV and influenza vaccine candidates based on GenVec's proprietary adenovirus vector and production cell line technologies. Under the contract, the vaccines would be comprised of genetic material supplied by the VRC and adenoviral vectors supplied by GenVec.

"An important focus of this collaboration is on the development of vaccines based on novel vectors that have the potential to elicit the appropriate immune response," stated Dr. Paul Fischer, GenVec's President and CEO.

GenVec and the NIAID Vaccine Research Center have partnered on HIV and influenza vaccine development for several years under Collaborative Research and Development Agreements utilizing GenVec's technologies.  Under a separate contract, GenVec has produced adenovector-based HIV vaccines that have been tested in approximately 1,400 subjects in sixteen NIAID-sponsored Phase I and Phase II clinical trials.  

About GenVecGenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses proprietary drug discovery and development technologies to support a portfolio of product programs that address the prevention and treatment of a number of major diseases.  In collaboration with Novartis, GenVec is developing novel treatments for hearing loss and balance disorders. GenVec also develops and is evaluating the potential of TNFerade for the treatment of certain cancers and is developing vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future milestone payments, royalties, the development of products and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.Contact:GenVec, Inc. Douglas J. Swirsky (240) 632-5510 dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, ... ... mystery. A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... in dogs. The study was published in the prestigious Journal of Veterinary Science ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is ... Awards under the Best New Product Launch category. Gensuite’s entry on their EZ ... , BOC Global Events & Training Group is a professional event and training ...
Breaking Medicine News(10 mins):